Slide 1: First Quarter 2021 Results
K Pharm First Quarter 2021 Results Trademarks referenced herein are held by their respective owners
Slide 2: Cautionary Note Regarding Presentation Information
Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended Forward-looking st
Slide 3: Q1 2021 Results Call Participants
Q1 2021 Results Call Participants + Travis Mickle, Ph.D. - President & Chief Executive Officer + R. LaDuane Clifton, CPA - Chief Financial Officer, Secretary & Treasurer
Slide 4: KemPharm: Q1 2021 and Recent Highlights
KemPharm: Q1 2021 and Recent Highlights AZSTARYS™ (KP415) FDA has approved AZSTARYS NDA Corium expected to launch in H2 2021 Now eligible to receive up to $590 million for regulatory and sales milestone payments, per amended License Agreement New top-level sales tier for royalty rates on U.S. net sa
Slide 5: AZSTARYS Approval
ASTARYS™ Approval v On March 2, 2021, the FDA approved AZSTARYS (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, Cll) ANew Once-Daily Treatment for ADHD Consists of serdexmethylphenidate (SDX), KemPharm’s prodrug of d- methylphenidate (d-MPH), co-formulated with immediate-releas
Slide 6: Amendment to License Agreement with Affiliate of GPC
Amendment to License Agreement wi Affiliate of GPC Vv Post-Approval commercial assessments conducted separately and together with the GPC team led to a renegotiation of the economic terms of the KP415 License Agreement Total potential regulatory and sales milestone payments increased to $590M from $
Slide 7: AZSTARYS Commercialization - Reasons for Optimism
AZSTARYS™ Commercialization - Reasons for Optimism Corium preparing for commercial launch as early as the second half of 2021 o Target date aligns with start of school in Aug./Sept. o Manufacturing validation underway o Corium is led by Perry Sternberg, President and CEO, as well as many other execu
Slide 8: Serdexmethylphenidate (SDX) — Schedule IV Classification
Serdexmethylphenidate (SDX) — Schedule IV Classification SDX recently classified as a Schedule IV Controlled Substance by DEA o AZSTARYS classified as a Schedule II controlled substance as it includes a 70:30 mixture of SDX (Schedule IV) and d-MPH (Schedule ll), respectively + SDX Schedule IV classi
Slide 9: Key Differences between Schedule C-II and C-IV
Key Differences between Schedule C-Il and C-IV Methylphenidate Products All Current Serdexmethylphenidate Methylphenidate Products (SDXx) Current DEA Schedule Cll CIV Refills Allowed? No Yes Duration of Script/Refills? None Up to 6 months total Delivery of Prescription Phone, fax, written or Written
Slide 10: Financial Update
Financial Update
Slide 11: Multi-Phase Financial Restructuring Completed
Multi-Phase Financial Restructuring Completed * Series of transactions enabled the restructure of the balance sheet and strengthened our financial position * Transactions culminated in aggregate gross proceeds of approximately $94 million, enabling KemPharm to: o Regain its listing on The Nasdaq Cap
Slide 12: Q1 2021 Financial Results
Q1 2021 Financial Results + Revenue of $12.1M, primarily comprised of a milestone payment of $10.0M related to the AZSTARYS NDA approval and services revenue of $2.1M under the Corium consulting arrangement + Net loss of ($10.3M), or ($0.54) per basic and diluted share, compared to net loss of ($5.8
Slide 13: Q1 2021 Balance Sheet Update
Q1 2021 Balance Sheet Update - As of Mar 31, 2021, total cash’ was $76.0M, an increase of $71.7M compared to Dec 31, 2020 * Total debt, net, of $67.7M at Dec 31, 2020, has been fully extinguished: o Paid $30.3M out of cash proceeds received in Jan 2021 offering o Converted $31.5M of principal and in
Slide 14: KemPharm: Looking Ahead
KemPharm: Looking Ahead AZSTARYS™ (KP415) - KemPharm continues to actively support Corium’s commercial launch effort which is expected in H2 2021 - Additional clinical work around preschool age group (4-5 yr.) expected in 2021 - Expect royalties and sales milestones in 2022 and beyond | Improved Fin
Slide 15: First Quarter 2021 Results
K Pharm First Quarter 2021 Results